Quanterix
Quanterix Projects Q4 2021 Revenues of $29M to $31M
The company projected full year 2021 revenues of $109 million to $111 million, up from $86.4 million in 2020.
The approval of Biogen's Alzheimer's disease treatment in June was seen as an important regulatory development for companies developing tests.Â
Quanterix Q3 Revenues Decline 12 Percent, Beat Wall Street Estimates
The firm posted Q3 revenues of $27.7 million, down from $31.4 million in Q3 2020, but excluding one-time license and grant revenue, revenues were up 46 percent.
In Brief This Week: Quanterix, Cue Health, Hologic, CareDx, and More
News items for the in vitro diagnostics industry for the week of Oct. 11, 2021.
Quanterix Revenues Almost Double in Q2
The company posted second quarter revenues of $25.4 million, up from $13.1 million in Q2 2020 and above the consensus Wall Street estimate of $23.4 million.
May 5, 2021
Quanterix Q1 Revenues up 73 Percent
Mar 2, 2021
Quanterix Q4 Revenues Up 64 Percent
Feb 4, 2021
Quanterix Prices $250M Public Stock Offering
Dec 28, 2020
Quanterix Gets FDA EUA for SARS-CoV-2 Antibody Test
Aug 7, 2020
Quanterix Prices $85M Public Stock Offering
May 6, 2020
Quanterix Q1 Revenues Up 27 Percent
Mar 9, 2020